Inflammatory Bowel Disease · Article 148

How Should Immunosuppressive IBD Therapy Be Managed During a Serious Infection?

IBD immunosuppression infection requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

IBD immunosuppression infection clinical reference — Related free clinical resource: First Principles of Gastroenterology and Hepatology.

IBD immunosuppression infection: practical clinical approach

This page focuses on IBD immunosuppression infection with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for IBD immunosuppression infection

Clinical takeaway: For IBD immunosuppression infection, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Management of IBD immunosuppression during serious infection must balance two risks: uncontrolled infection and uncontrolled IBD. Severe sepsis or an uncontrolled invasive infection often justifies temporary interruption of selected biologic or small-molecule therapy while source control and antimicrobial therapy begin. Corticosteroids should not be abruptly stopped in steroid-dependent patients because adrenal insufficiency can be dangerous. Disease-specific exceptions matter: the 2026 AGA update on C. difficile recommends continuing necessary IBD immunosuppression while CDI is treated.

Define infection severity

A mild treated infection is different from bacteremia, opportunistic infection or septic shock. Drug half-life also matters; ‘holding’ a biologic dose does not instantly remove its effect.

Steroids require special handling

Chronic corticosteroids increase infection risk, yet abrupt withdrawal can cause adrenal crisis. Use stress-dose steroids when indicated and taper when clinically safe.

Restart deliberately

Once infection is controlled, delay in restarting effective IBD therapy can precipitate a flare. Coordinate with infectious-disease specialists for opportunistic infections.

Practical clinical algorithm

1. Identify the infection, source and severity.

2. Determine each IBD drug’s mechanism, half-life and immediate necessity.

3. Provide source control and targeted antimicrobials.

4. Temporarily hold selected advanced therapy in severe uncontrolled infection when appropriate.

5. Avoid abrupt steroid withdrawal.

6. Restart effective IBD therapy once infection control permits.

Common mistakes to avoid

One rule for every infection and every drug.
Abruptly stopping chronic steroids.
Forgetting latent/reactivation infections specific to drug class.
Holding therapy so long that IBD flares severely.
Ignoring the CDI-specific recommendation to treat infection and IBD concurrently.

Trainee takeaway

Think mechanism-by-mechanism and infection-by-infection; blanket immunosuppression rules are clinically unsafe.

Frequently asked questions

Should every fever lead to a held biologic dose?

No. Severity and cause matter.

What about sepsis?

Severe uncontrolled infection usually warrants temporary interruption of selected advanced therapies while treatment begins.

When can therapy restart?

When infection is adequately controlled and the benefits of IBD control again outweigh infectious risk.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

3. Khanna S, et al. AGA Clinical Practice Update on CDI in IBD. Gastroenterology. 2026.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions